

Financial news for SRNE dated on 2020-06-05: UPDATE: Sorrento Therapeutics Says COVIDTRAP 'binds strongly to the spike protein of the SARS-CoV-2 virus,' neutralizes the SARS-CoV-2 virus and prevents infection in African green monkey kidney epithelial cells in vitro at low concentration'

Financial news for SRNE dated on 2020-06-05: Sorrento Therapeutics shares are trading higher after the company reportedly announced its STI-4398 demonstrated ability in preclinical studies to completely inhibit the Sars-Cov-2 viral infection in vitro.

Financial news for SRNE dated on 2020-06-05: Sorrento Therapeutics Say Company's STI-4398 Demonstrates Ability In Preclinical Studies To Completely Inhibit Sars-Cov-2 Viral Infection In Vitro

Financial news for SRNE dated on 2020-05-26: Sorrento Therapeutics shares are trading higher after the company received FDA IND clearance to initiate the Phase I clinical trial of its CD38 antibody-drug conjugate STI-6129 for patients with amyloidosis.

Financial news for SRNE dated on 2020-05-26: Sorrento Receives FDA IND Clearance To Initiate Phase I Clinical Trial Of Its CD38 Antibody-Drug Conjugate (ADC) STI-6129 For Patients With Amyloidosis

Financial news for SRNE dated on 2020-05-26: Dawson James Initiates Coverage On Sorrento Therapeutics with Buy Rating, Announces Price Target of \$24

Financial news for SRNE dated on 2020-05-26: Hearing Dawson James Initiates Sorrento Therapeutics With Buy, Announces \$24 Price Target

Financial news for SRNE dated on 2020-05-26: Dow Jones Market Talk Article Titled 'Sorrento's Coronavirus Drug Offers a Big Opportunity' Discusses Buy Recommendation On Stock From Dawson James Securities?

Financial news for SRNE dated on 2020-05-22: Hindenburg Research Says 'The \$SRNE CEO walked back his comments about having a cure moments ago We believe this amounts to flagrant securities fraud when compared to his statements to Fox last week. We encourage regulators to investigate any stock sales

Financial news for SRNE dated on 2020-05-22: Sorrento Shares Dropping Lower After Hindenburg Research Tweets Out CEO Comments

Financial news for SRNE dated on 2020-05-22: Sorrento Therapeutics Shares On Watch As Traders Circulate Thursday WealthWise Podcast With Doctors From Co.

Financial news for SRNE dated on 2020-05-21: Sorrento Therapeutics shares are trading lower on continued weakness following a Wednesday short report.

Financial news for SRNE dated on 2020-05-21: Sorrento Enters Binding Term Sheet To Buy Exclusive Rights To Abivertinib With Completed Registrational Trial Data In Non-Small Cell Lung Cancer

Financial news for SRNE dated on 2020-05-20: Sorrento Shares Ticking Lower As Viceroy Tweets Short Position

Financial news for SRNE dated on 2020-05-20: Sorrento Therapeutics Shares Down 15%; Short Seller Hindenburg Research Publishes 'Sorrento's Pandemic Profiteering: Experts and Former Employees Speak Out on Sensational Claims of Covid-19 Cure'

Financial news for SRNE dated on 2020-05-18: Sorrento Therapeutics Shares Halted On Circuit Breaker, Down Sharply From Session High But Still Up 27.5% For Session

Financial news for SRNE dated on 2020-05-15: STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies

Financial news for SRNE dated on 2020-05-15: 'Reports that \$SRNE has something against Covid will gun the stock, please be careful.. very small cap' -Tweet From Jim Cramer

Financial news for SRNE dated on 2020-05-15: Sorrento Therapeutics shares are trading higher amid investor attention surrounding the company's STI-1499 coronavirus antibody.

Financial news for SRNE dated on 2020-05-15: Sorrento Therapeutics Says Coronavirus Antibody STI-1499 Showed Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies, Indicates Potentially Strong Antibody Drug Candidate

Financial news for SRNE dated on 2020-05-15: 'California biopharmaceutical company claims coronavirus antibody breakthrough' -FOX News

Financial news for SRNE dated on 2020-05-08: Shares of several healthcare companies

are trading higher after US unemployment figures came in below consensus estimates. Equities have been strong this week amid a rebound in oil prices and some US states easing lockdown restrictions.

Financial news for SRNE dated on 2020-05-08: Sorrento Press Release Confirms Partnership With Mount Sinai

Financial news for SRNE dated on 2020-05-08: UPDATE: Sorrento Sees Beginning Phase 1 Trials Of Antibody Therapy To Potentially Treat Coronavirus In Q3'20

Financial news for SRNE dated on 2020-05-08: Sorrento Therapeutics Reports Partnership With Mount Sinai Health To Jointly Develop Covi-Shield Antibody Therapy Against Coronavirus

Financial news for SRNE dated on 2020-04-27: Sorrento Therapeutics Filing Shows Registration For \$250M Common Stock Shelf Offering

Financial news for SRNE dated on 2020-04-02: Sorrento To Provide Manufacturing Support To Celularity As CYNT-001 NK Cell Trial For Coronavirus Begins Enrolling Patients

Financial news for SRNE dated on 2020-03-31: Sorrento And The University Of Texas Medical Branch At Galveston Enter Into Preclinical Testing Agreement For Coronavirus Therapeutic Candidates

Financial news for SRNE dated on 2020-03-31: Sorrento Therapeutics Announces On March 31, Co & Nanjing Hongjing Enterprise Management Consulting Co. Entered Into Binding Term Sheet; Co To Sell To Nanjing Hongjing Certain Assets Related To Company's Operations In China, Nanjing Hongjing To Pay \$30M

Financial news for SRNE dated on 2020-03-30: H.C. Wainwright Reiterates Buy on Sorrento Therapeutics, Lowers Price Target to \$24

Financial news for SRNE dated on 2020-03-25: UPDATE: Sorrento Says Is In Active Talks With FDA's Center For Biologics Evaluation, Research To Gain Guidance On Rapid Development Of Novel Vaccine

Financial news for SRNE dated on 2020-03-25: UPDATE: Sorrento Says 'STI-6991 is an I-Cell™ COVID-19 cellular vaccine made of replication-deficient human erythro leukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus'

Financial news for SRNE dated on 2020-03-25: Sorrento Therapeutics Highlights Launch Of Novel I-Cell Coronavirus Cellular Vaccine Program

Financial news for SRNE dated on 2020-03-24: Sorrento Therapeutics Reports Collaboration With Mabpharm On Development, Commercialization Of ACE-MAB To Potentially Treat Coronavirus

Financial news for SRNE dated on 2020-03-23: Sorrento Therapeutics Reports Collaboration With SmartPharm To Develop Gene-Encoded Antibody Vaccine Intended To Protect Against Coronavirus

Financial news for SRNE dated on 2020-03-20: Sorrento Therapeutics Reports Development Of 'COVIDTRAP Protein' For Potential Prevention, Treatment Of Coronavirus Disease

Financial news for SRNE dated on 2020-03-05: Sorrento Therapeutics Shares Were Volatile Around 2 p.m. EST Around Time Of Disclosure Of 40K Share Buy By Director Robin Smith

Financial news for SRNE dated on 2020-03-05: Sorrento Therapeutics shares are trading higher as traders circulate bullish blog post suggesting a possible coronavirus play.

Financial news for SRNE dated on 2020-03-05: Sorrento Therapeutics Shares Spike To Session High, Now Up 10%, Amid Circulation Of Seeking Alpha Blog Post From Tues. 'Covid-19 Virus Spreads, Sorrento Therapeutics Stock Is A Buy Say Analysts Offering 1000% Upside'

Financial news for SRNE dated on 2020-02-27: Sorrento Therapeutics Highlights Presentation Of Interim Results Of Phase 1b RTX In Cancer Pain Trial

Financial news for SRNE dated on 2020-02-27: Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, At LEERINK Global Healthcare Conference

Financial news for SRNE dated on 2020-01-29: Sorrento Therapeutics Files For 2M Share Offering Of Common Stock By Selling Shareholders

Financial news for SRNE dated on 2020-01-29: Sorrento And Celularity To Initiate

Emergency Allogeneic Natural Killer Cell Therapy Development For Coronavirus Infection

Financial news for SRNE dated on 2020-01-27: Sorrento Therapeutics shares are trading lower after the company's board rejected a private equity offer of \$7 per share to acquire the company.

Financial news for SRNE dated on 2020-01-27: Sorrento's Board Rejects the Private Equity \$7/Share Acquisition Offer

Financial news for SRNE dated on 2020-01-13: Sorrento Therapeutics shares are trading lower, reversing from Friday strength following an acquisition proposal from a private equity firm for \$7/share.

Financial news for SRNE dated on 2020-01-10: Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR

Financial news for SRNE dated on 2020-01-10: Sorrento Therapeutics shares are trading higher after the company announced it has received a non-binding acquisition proposal from a private equity fund for \$7 per share.

Financial news for SRNE dated on 2020-01-10: Sorrento Therapeutics Reports Received Non-Binding Acquisition Proposal At \$7/Share

Financial news for SRNE dated on 2020-01-06: Sorrento Therapeutics Files for a New Drug Application for the Infliximab Biosimilar Antibody in China

Financial news for SRNE dated on 2019-12-20: Sorrento Therapeutics shares are trading lower. Not currently seeing any company-specific news.

Financial news for SRNE dated on 2019-12-11: Sorrento Therapeutics shares are trading higher. Not currently seeing any company-specific news.

Financial news for SRNE dated on 2019-12-09: Sorrento Therapeutics shares are trading higher after the company announced a change in board members.

Financial news for SRNE dated on 2019-12-05: Sorrento Therapeutics shares are trading lower as a potential sell-off after the stock increased roughly 135% since November 22.

Financial news for SRNE dated on 2019-12-03: Sorrento Therapeutics shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock is trading on above-average volume.

Financial news for SRNE dated on 2019-12-02: Sorrento Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for SRNE dated on 2019-11-27: Sorrento Therapeutics shares are trading lower. Not seeing any news to justify the price action.

Financial news for SRNE dated on 2019-11-25: Sorrento Therapeutics shares are trading higher after the company announced it has received and rejected an unsolicited, all cash proposal from two biopharmaceutical companies between \$3-\$5 per share in cash.

Financial news for SRNE dated on 2019-11-25: Sorrento Therapeutics Shares To Resume Trade At 7:30 a.m. EST

Financial news for SRNE dated on 2019-11-25: Sorrento Therapeutics Shares Halted to Announce Co. Received, Rejected Unsolicited All-Cash Proposal From 2 Biopharma Cos. Between \$3-\$5/Share In Cash

Financial news for SRNE dated on 2019-10-16: Sorrento Therapeutics shares are trading higher despite no company-specific news. This could potentially be a rebound after the stock dropped approximately 35% over the past 7 trading sessions.

Financial news for SRNE dated on 2019-10-07: Sorrento Therapeutics Announces \$25M Registered Direct Offering; ~10.87M Shares At \$2.30/Share And Related Warrant

Financial news for SRNE dated on 2019-10-07: JMP Securities Initiates Coverage On Sorrento Therapeutics with Market Outperform Rating, Announces \$21 Price Target

Financial news for SRNE dated on 2019-09-23: Sorrento Therapeutics Subsidiary Scilex Files an S-1 to the SEC for its Proposed IPO

Financial news for SRNE dated on 2019-06-28: Sorrento Therapeutics Prices 8.333M Shares At \$3/Share

Financial news for SRNE dated on 2019-06-28: Sorrento Therapeutics shares are trading lower after the company reported an offering of common stock and warrants.

Financial news for SRNE dated on 2019-06-19: UPDATE: Sorrento Says 'All dose groups had treatment effect size traditionally considered sufficient for approval by Regulators.'

Financial news for SRNE dated on 2019-06-19: Sorrento Therapeutics Offers Updates On Results Of Phase 1b RTX In Knee Osteoarthritis Pain Trial

Financial news for SRNE dated on 2019-06-19: Sorrento Therapeutics Offers Updates On CD38 Immunotherapies, Implementation Of Disruptive GMP Manufacturing For Off The Shell Cell Therapy

Financial news for SRNE dated on 2019-06-17: Sorrento Therapeutics S-3 Shows Registration For ~1.33M Share Common Stock Offering Via Selling Shareholders

Financial news for SRNE dated on 2019-06-12: Sorrento To Explore Potential Initial Public Offering Of Scilex Holding Company

Financial news for SRNE dated on 2019-06-10: Sorrento Therapeutics Reports Acceleration Of Human Investigational New Drug Filing Of Resiniferatoxin For Prolonged Non-Opioid Control Of Post-Amputation Neuropathic Pain

Financial news for SRNE dated on 2019-06-05: Sorrento Therapeutics Reports May ZTlido Sales \$3.3M, Up From \$2.4M In April; Says SP-102 Pivotal Phase 3 Trial Remains On Track For Completion In First Half Of 2020

Financial news for SRNE dated on 2019-06-04: Sorrento Therapeutics shares are higher after the company announced a global joint venture and commercial strategic partnership in China for its cannabidiol formulation technologies.

Financial news for SRNE dated on 2019-06-04: Sorrento Announces Cannabidiol (CBD) Global Joint Ventures And Commercial Strategic Partnerships

Financial news for SRNE dated on 2019-04-16: Sorrento Therapeutics Establishes New Business Unit To Focus On Water-Soluble CBD Formulation Technology

Financial news for SRNE dated on 2019-04-10: Sorrento Therapeutics shares are trading higher after the company announced positive topline results in a discovery trial of a potential non-dopaminergic approach to controlling Parkinson's motor symptoms with Resiniferatoxin Intrathecal Administration.

Financial news for SRNE dated on 2019-04-10: Sorrento Therapeutics Announces Discovery Of A Potential Non-Dopaminergic Approach To Controlling Parkinson's Motor Symptoms With Resiniferatoxin Intrathecal Administration, Announces 'Positive And Better Than Initially Hoped For' Top Line Results

Financial news for SRNE dated on 2019-04-03: Patrick Soon-Shiong Says Lawsuit By Sorrento Therapeutics Is 'Without Merit', Intends To Defend It

Financial news for SRNE dated on 2019-04-03: Sorrento Therapeutics shares are trading higher after the company filed legal actions against Patrick Soon-Shiong, asserting claims for fraud and breach of contract regarding his purchase of the drug Cynviloq.

Financial news for SRNE dated on 2019-04-03: Sorrento Therapeutics 8-K Shows Co. Filed 2 Legal Actions Against Patrick Soon-Shiong And Entities Controlled By Him Asserting Claims For Fraud, Breach Of Contract Following Purchase Of Cynviloq In May 2015

Financial news for SRNE dated on 2019-03-29: Top 15 Most-Volatile Stocks For Fri., Mar. 29, 2019 Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets

Financial news for SRNE dated on 2019-03-27: Sorrento Therapeutics shares are trading lower in a potential sell off following recent strength. The company recently presented at Oppenheimer's healthcare conference and on Tuesday, its subsidiary Scilex Holdings published positive Phase 2 results.

Financial news for SRNE dated on 2019-03-26: Sorrento Therapeutics shares are trading higher after the company reported its majority-owned subsidiary Scilex published positive results for its Phase 2 trial of SP-100 and is proceeding as planned with a Phase 3 study.

Financial news for SRNE dated on 2019-03-26: Sorrento Says Scilex's SP-102 Phase 3 Trial Is Proceeding As Planned, Has Reached Near 50% Enrollment Completion

Financial news for SRNE dated on 2019-03-26: Sorrento Therapeutics Reports Its Majority-Owned Subsidiary Scilex Holdings Published Results Of Phase 2 Trial For SP-102 In Patients With Sciatica: 'All subjects experienced rapid reduction of leg and back pain...'

Financial news for SRNE dated on 2019-03-26: Top 15 Most-Volatile Stocks For Tues., Mar. 26, 2019 Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets

Financial news for SRNE dated on 2019-03-25: Sorrento Therapeutics shares are trading lower as the stock pulls back from a 155% climb in price last week.

Financial news for SRNE dated on 2019-03-22: Sorrento Therapeutics shares are trading higher after the company announced the merger of Scilex and Semnur.

Financial news for SRNE dated on 2019-03-22: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 22, 2019

Financial news for SRNE dated on 2019-03-21: Sorrento Therapeutics shares are trading higher after the company presented at Oppenheimer's healthcare conference in New York on Wednesday.

Financial news for SRNE dated on 2019-03-20: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Mar. 20, 2019

Financial news for SRNE dated on 2019-03-20: B. Riley Maintains Buy On Sorrento Therapeutics And Raises Price Target From \$10.50 To \$12/Share; Firm Cites 'Numerous Catalysts' With High-Value/Late-Stage Candidates

Financial news for SRNE dated on 2019-03-19: Sorrento Therapeutics shares are trading higher ahead of the company's Wednesday presentation at Oppenheimer's healthcare conference in New York.

Financial news for SRNE dated on 2019-03-15: Sorrento Therapeutics Filing Shows Registration For \$100M Common Stock Offering

Financial news for SRNE dated on 2019-03-11: Sorrento Therapeutics Will Not Conduct a Phase 2 Study with Yuhan of Anti-PD-L1 Antibody IMC-001

Financial news for SRNE dated on 2019-01-22: Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With 'Positive' Therapeutic Signal And Absence Of Dose Limiting Toxicities

Financial news for SRNE dated on 2018-11-06: Sorrento Therapeutics Reports Anti-CEA CAR-T Showed Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases

Financial news for SRNE dated on 2018-11-01: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Financial news for SRNE dated on 2018-10-03: Sorrento Therapeutics Shares Down 4%; Mox Reports Recently Tweeted 'short \$SRNE'

Financial news for SRNE dated on 2018-09-10: Sorrento Therapeutics shares are up 7.6% after the company earlier announced its Scilex Pharmaceuticals Inc has received \$140 million in royalty-based financing to support the commercialization of ZTlido pain medication.

Financial news for SRNE dated on 2018-08-13: Sorrento Announces 1st Patient Treated for Osteoarthritis Knee Pain in Resiniferatoxin Phase 1b Trial Meets Both Safety and Efficacy Expectations

Financial news for SRNE dated on 2018-07-03: Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics, Terms Not Disclosed

Financial news for SRNE dated on 2018-06-28: B. Riley FBR Initiates Coverage On Sorrento Therapeutics with Buy Rating, Announces \$14.25 Price Target

Financial news for SRNE dated on 2018-05-11: Sorrento Therapeutics Files for Resale of 1,381,345 Shares by Selling Shareholders

Financial news for SRNE dated on 2018-05-11: Sorrento Therapeutics Files for Resale of 34,159,77 Shares by Selling Shareholders

Financial news for SRNE dated on 2018-04-05: Sorrento Therapeutics And Celularity Begin Anti-CD38 CAR-T Phase 1 Clinical Trial

Financial news for SRNE dated on 2018-03-27: Sorrento Therapeutics Shares Dip To Session Lows As Traders Circulate SeekingAlpha Article From J Capital Suggesting Stock Is 'A Zero'

Financial news for SRNE dated on 2018-03-19: Sorrento Therapeutics Announces join Shao CFO

Financial news for SRNE dated on 2018-03-01: Benzinga Pro's Top 10 Most-Searchd Tickers During The Morning Of Thurs., Mar. 1

Financial news for SRNE dated on 2018-02-28: UPDATE: HC Wainwright Values Sorrento's Celularity Stake At \$1.4B, ZTlido At \$1.3B, Up From \$800M Prior To Approval

Financial news for SRNE dated on 2018-02-28: UPDATE: HC Wainwright On Sorrento Says Modeling For Peak ZTlido US Sales \$1B+ By '25

Financial news for SRNE dated on 2018-02-28: Sorrento Shares At Session Highs, Now Up 17%; HC Wainwright Recently Issued Mid-Day Note Setting \$38 Price Target On Stock, Reiterating Buy Rating

Financial news for SRNE dated on 2018-02-28: Sorrento Therapeutics Shares Resume Trade, Now Up 3.4% For Session

Financial news for SRNE dated on 2018-02-28: Sorrento Therapeutics Shares To Resume Trade At 2:45 p.m. EST

Financial news for SRNE dated on 2018-02-28: UPDATE: Sorrento Therapeutics Says It Will Explore Expansion Of ZTlido Into Additional Indications And The Underlining Platform Tech Of ZTlido For Other APIs And Combination Of APIs

Financial news for SRNE dated on 2018-02-28: Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido 1.8% for PHN Pain

Financial news for SRNE dated on 2018-02-28: Sorrento Therapeutics Shares Halted News Pending

Financial news for SRNE dated on 2018-02-08: Earlier Form 4 Filing Shows Sorrento Therapeutics 10% Owner Ally Bridge Group Sold 662.912K Shares At Avg. Prices Ranging From \$6.75 to \$7.19

Financial news for SRNE dated on 2018-02-05: Sorrento's JV ImmuneOncia Receives Approval To Begin Trial Of Anti-PD-L1 Monoclonal Antibody In South Korea

Financial news for SRNE dated on 2018-02-05: Sorrento's and Yuhan's Joint Venture, ImmuneOncia, Receives Approval to Begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea

Financial news for SRNE dated on 2018-02-05: Sorrento Therapeutics Issues Letter To Shareholders

Financial news for SRNE dated on 2018-01-23: Sorrento Therapeutics Shares Make Mid-Day Parabolic Move, Spike ~\$0.40 High Then Quickly Give Up Near-Term Gains; Traders Circulated Vague Chatter In Name

Financial news for SRNE dated on 2018-01-23: HC Wainwright Analyst Raghuram Selvaraju Believes 'Juno Acquisition Bodes Well For Sorrento'; Reiterated Buy Rating, \$30 Price Target

Financial news for SRNE dated on 2018-01-23: Sorrento Therapeutics Shares Closed Mon. Up 21%; Form 4 Shows Pres, CEO Henry Ji Purchased ~1.8M Shares On Jan. 21

Financial news for SRNE dated on 2018-01-17: Sorrento Therapeutics Shares Continuing Higher Wed., Up 7.8%, Following 16% Rally On Tues.; Stock Up ~140% Since Mid Dec.; Have Not Seen News To Justify Price Action, But Important To Note Price Moved Over 2 Important Technical Levels At \$5, \$6

Financial news for SRNE dated on 2018-01-02: Sorrento Therapeutics Shares Up 13.81%; Earlier Co. Announced CEO Henry Ji To Present "Game-Changer" CAR-T Tech At East/West CEO Conference Saturday Jan. 6th

Financial news for SRNE dated on 2017-12-11: Sorrento Therapeutics 8-K Shows Co. Entered Securities Purchase Deal With Accredited Invesotrs For \$50M In Promissory Notes

Financial news for SRNE dated on 2017-11-09: Sorrento Therapeutics S-3 Filing Shows Registration For \$350M Mixed Securities Offering

Financial news for SRNE dated on 2017-09-12: FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido, PDUFA Date Set For February 28, 2018

Financial news for SRNE dated on 2017-08-04: Oppenheimer Initiates Coverage On Sorrento Therapeutics with Outperform Rating, Announces \$7.00 Price Target

Financial news for SRNE dated on 2017-07-26: Companies Holding Shareholder Meetings Today Include: Greenhill & Co, McKesson, MGIC Investment, Newtek, Riverview Bancorp, Sorrento Therapeutics, and Thermon Group

Financial news for SRNE dated on 2017-06-29: Sorrento Therapeutics Announces FDA Authorization of IND To Begin Trial of RTX

Financial news for SRNE dated on 2017-06-26: Sorrento Therapeutics Subsidiary Semnur Pharma Gives Update on 'Successful' Phase 1/2 Trial

Financial news for SRNE dated on 2017-06-14: Sorrento Therapeutics Reports Dismissal of Suits

Financial news for SRNE dated on 2017-06-14: Sorrento Therapeutics Subsidiary SCILEX Announces Positive Data In Comparative Adhesion Performance Study

Financial news for SRNE dated on 2017-05-19: White Diamond Research Analyst Adam Gefvert Tweets: Just got news that the CFO of \$SRNE is leaving. The company told me when I tried to reach investor relations. Seems bearish.

Financial news for SRNE dated on 2017-05-04: Sorrento Therapeutics Reports the Completion of GMP Manufacturing Plant in Suzhou

Financial news for SRNE dated on 2017-04-13: Sorrento Therapeutics Prices Offering of 23.625M Shares at \$2/Share

Financial news for SRNE dated on 2017-04-12: Sorrento Reports Proposed Public Offering of Common Stock

Financial news for SRNE dated on 2017-03-20: Sorrento, Wildcat Capital Announce Resolution To Wildcat's Claims Seeking Inspection Of Documents Related To Company's Private Placement Agreements

Financial news for SRNE dated on 2017-01-09: Sorrento Says Endpoints Met in European Union Pivotal Bioequivalence Clinical Study for ZTlido

Financial news for SRNE dated on 2016-10-03: Roth Capital Initiates Coverage on Sorrento Therapeutics at Buy

Financial news for SRNE dated on 2016-04-05: Rodman & Renshaw Maintains Buy on Sorrento Therapeutics, Lowers PT to \$30.00

Financial news for SRNE dated on 2016-02-29: Rodman & Renshaw Maintains Buy on Sorrento Therapeutics, Lowers PT to \$40.00

Financial news for SRNE dated on 2015-12-22: FBR Capital Initiates Coverage on Sorrento Therapeutics at Outperform, Announces \$22.00 PT

Financial news for SRNE dated on 2015-12-07: H.C. Wainwright Assumes Sorrento Therapeutics at Buy, Announces \$45.00 PT; Says Firm Is 'emerging biopharma' With 'Best In Class' Cell Based Immunotherapy Approach

Financial news for SRNE dated on 2015-05-28: Brean Capital Initiates Coverage on Sorrento Therapeutics at Buy, Announces \$17.00 PT

Financial news for SRNE dated on 2015-05-19: Advaxis, Sorrento Announces Collaboration

Financial news for SRNE dated on 2015-05-01: Sorrento Acquires South American Rights to Cynviloq

Financial news for SRNE dated on 2014-12-19: Sorrento, Conkwest Announce Exclusive Global Collaboration

Financial news for SRNE dated on 2014-07-01: Sorrento Awarded Up To \$2.6M From Government For Development of New Anti Bacterial Antibodies

Financial news for SRNE dated on 2014-06-25: Morphotek and Sorrento Sign Research Agreement for Morphotek Antibody Drug Conjugates

Financial news for SRNE dated on 2014-06-23: Sorrento Announces Filing of S-1 For Potential IPO for Subsidiary Ark Animal Health

Financial news for SRNE dated on 2014-06-19: UPDATE: MLV & Co. Initiates Coverage On Sorrento Therapeutics On Good Cynviloq Potential

Financial news for SRNE dated on 2014-05-15: Afternoon Market Movers

Financial news for SRNE dated on 2014-05-15: Stocks Hitting 52-Week Lows

Financial news for SRNE dated on 2014-05-15: Morning Market Losers

Financial news for SRNE dated on 2014-05-15: UPDATE: Sorrento Therapeutics Shares Fall 30% Premarket Following Pricing of Offering at \$5.25/Share

Financial news for SRNE dated on 2014-05-15: US Stock Futures Flat Ahead Of Economic Data, Wal-Mart Earnings

Financial news for SRNE dated on 2014-05-15: Sorrento Therapeutics Prices 4.765M Share IPO at \$5.25/Share

Financial news for SRNE dated on 2014-05-14: Sorrento Announces Offering, No Details Disclosed

Financial news for SRNE dated on 2014-05-13: Sorrento Announces Transfer of Orphan Drug Designation for Intrathecal Resiniferatoxin from NIH

Financial news for SRNE dated on 2014-04-04: Sorrento Presents Positive Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting

Financial news for SRNE dated on 2014-04-04: Sorrento Says Resiniferatoxin Appears Well-Tolerated With No Opioid-Like Toxicities

Financial news for SRNE dated on 2014-04-01: Sorrento Announces First Patient Dosed in TRIBECA Trial

Financial news for SRNE dated on 2013-12-19: Stocks Hitting 52-Week Lows

Financial news for SRNE dated on 2013-12-19: OPKO Completes Sale of Sorrento Therapeutics Stake

Financial news for SRNE dated on 2013-12-04: UPDATE: Aegis Capital Initiates Coverage On Sorrento Therapeutics On RTX-100

Financial news for SRNE dated on 2013-11-12: Sorrento Therapeutics Adopts Stockholder Rights Plan

Financial news for SRNE dated on 2013-10-25: US Stock Futures Flat Ahead Of Durable-Goods Data

Financial news for SRNE dated on 2013-10-25: Sorrento Therapeutics Prices 4.15M Share Offering at \$7.25/Share